Conference
Abstract CT097: IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study
Abstract
Abstract Background: IMM27M is a humanized Fc-engineered IgG1 CTLA-4 monoclonal antibody with enhanced ADCC. In pre-clinical models, IMM27M could enhance immune responses and promote Treg depletion. The pre-clinical results showed IMM27M induced a significantly stronger anti-tumor activity than ipilimumab and resulted in complete tumor remission even at a low dose. Methods: This study is an open-label, multi-center, phase I dose-escalation …
Authors
Wang S; Zheng Q; Gao Q; Zhang Q; Wu S; Li Z; Li E; Lu Q; Gan F; Tian W
Volume
84
Pagination
pp. ct097-ct097
Publisher
American Association for Cancer Research (AACR)
Publication Date
April 5, 2024
DOI
10.1158/1538-7445.am2024-ct097
Conference proceedings
Cancer Research
Issue
7_Supplement
ISSN
0008-5472